Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J. Anal. Oncol. 2015;4(3): 94-101. doi:10.6000/1927-7229.2015.04.03.1